Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life

Angelo Antonini, Silvana Tesei, Anna Zecchinelli, Paolo Barone, Danilo De Gaspari, Margherita Canesi, Giorgio Sacilotto, Nicotta Meucci, Claudio Mariani, Gianni Pezzoli

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

We assessed the effect of 3-month treatment of sertraline (50 mg) or low-dose amitriptyline (25 mg) on depression and quality of life in 31 patients with Parkinson's disease in a prospective single-blind randomized study. Both drugs significantly reduced the Hamilton Depression Rating Scale (HDRS-17) score. Completion rate was 75% for sertra-line (12 of 16) and 73% for amitriptyline (11 of 15). Responder rate (HDRS-17 score reduction ≥ 50%) was 83.3% for sertra-line and 72.7% for amitriptyline. Sertraline but not amitripty-line treatment determined a significant benefit on quality of life (PDQ-39 scale). We found no change in Unified Parkinson's Disease Rating Scale scores. However, the improvement in specific PDQ-39 subscores (mobility, activities of daily living, and stigma) suggests that depression affects patient self-perception of motor function and further emphasizes the need for its treament.

Original languageEnglish
Pages (from-to)1119-1122
Number of pages4
JournalMovement Disorders
Volume21
Issue number8
DOIs
Publication statusPublished - Aug 2006

Fingerprint

Sertraline
Amitriptyline
Parkinson Disease
Quality of Life
Depression
Single-Blind Method
Activities of Daily Living
Self Concept
Therapeutics
Pharmaceutical Preparations
propylene diquat

Keywords

  • Amitriptyline
  • Depression
  • Parkinson's disease
  • Sertraline

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Antonini, A., Tesei, S., Zecchinelli, A., Barone, P., De Gaspari, D., Canesi, M., ... Pezzoli, G. (2006). Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life. Movement Disorders, 21(8), 1119-1122. https://doi.org/10.1002/mds.20895

Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression : Effect on quality of life. / Antonini, Angelo; Tesei, Silvana; Zecchinelli, Anna; Barone, Paolo; De Gaspari, Danilo; Canesi, Margherita; Sacilotto, Giorgio; Meucci, Nicotta; Mariani, Claudio; Pezzoli, Gianni.

In: Movement Disorders, Vol. 21, No. 8, 08.2006, p. 1119-1122.

Research output: Contribution to journalArticle

Antonini, A, Tesei, S, Zecchinelli, A, Barone, P, De Gaspari, D, Canesi, M, Sacilotto, G, Meucci, N, Mariani, C & Pezzoli, G 2006, 'Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life', Movement Disorders, vol. 21, no. 8, pp. 1119-1122. https://doi.org/10.1002/mds.20895
Antonini, Angelo ; Tesei, Silvana ; Zecchinelli, Anna ; Barone, Paolo ; De Gaspari, Danilo ; Canesi, Margherita ; Sacilotto, Giorgio ; Meucci, Nicotta ; Mariani, Claudio ; Pezzoli, Gianni. / Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression : Effect on quality of life. In: Movement Disorders. 2006 ; Vol. 21, No. 8. pp. 1119-1122.
@article{ff156d0e1e724443829aa82e248ad5d0,
title = "Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life",
abstract = "We assessed the effect of 3-month treatment of sertraline (50 mg) or low-dose amitriptyline (25 mg) on depression and quality of life in 31 patients with Parkinson's disease in a prospective single-blind randomized study. Both drugs significantly reduced the Hamilton Depression Rating Scale (HDRS-17) score. Completion rate was 75{\%} for sertra-line (12 of 16) and 73{\%} for amitriptyline (11 of 15). Responder rate (HDRS-17 score reduction ≥ 50{\%}) was 83.3{\%} for sertra-line and 72.7{\%} for amitriptyline. Sertraline but not amitripty-line treatment determined a significant benefit on quality of life (PDQ-39 scale). We found no change in Unified Parkinson's Disease Rating Scale scores. However, the improvement in specific PDQ-39 subscores (mobility, activities of daily living, and stigma) suggests that depression affects patient self-perception of motor function and further emphasizes the need for its treament.",
keywords = "Amitriptyline, Depression, Parkinson's disease, Sertraline",
author = "Angelo Antonini and Silvana Tesei and Anna Zecchinelli and Paolo Barone and {De Gaspari}, Danilo and Margherita Canesi and Giorgio Sacilotto and Nicotta Meucci and Claudio Mariani and Gianni Pezzoli",
year = "2006",
month = "8",
doi = "10.1002/mds.20895",
language = "English",
volume = "21",
pages = "1119--1122",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression

T2 - Effect on quality of life

AU - Antonini, Angelo

AU - Tesei, Silvana

AU - Zecchinelli, Anna

AU - Barone, Paolo

AU - De Gaspari, Danilo

AU - Canesi, Margherita

AU - Sacilotto, Giorgio

AU - Meucci, Nicotta

AU - Mariani, Claudio

AU - Pezzoli, Gianni

PY - 2006/8

Y1 - 2006/8

N2 - We assessed the effect of 3-month treatment of sertraline (50 mg) or low-dose amitriptyline (25 mg) on depression and quality of life in 31 patients with Parkinson's disease in a prospective single-blind randomized study. Both drugs significantly reduced the Hamilton Depression Rating Scale (HDRS-17) score. Completion rate was 75% for sertra-line (12 of 16) and 73% for amitriptyline (11 of 15). Responder rate (HDRS-17 score reduction ≥ 50%) was 83.3% for sertra-line and 72.7% for amitriptyline. Sertraline but not amitripty-line treatment determined a significant benefit on quality of life (PDQ-39 scale). We found no change in Unified Parkinson's Disease Rating Scale scores. However, the improvement in specific PDQ-39 subscores (mobility, activities of daily living, and stigma) suggests that depression affects patient self-perception of motor function and further emphasizes the need for its treament.

AB - We assessed the effect of 3-month treatment of sertraline (50 mg) or low-dose amitriptyline (25 mg) on depression and quality of life in 31 patients with Parkinson's disease in a prospective single-blind randomized study. Both drugs significantly reduced the Hamilton Depression Rating Scale (HDRS-17) score. Completion rate was 75% for sertra-line (12 of 16) and 73% for amitriptyline (11 of 15). Responder rate (HDRS-17 score reduction ≥ 50%) was 83.3% for sertra-line and 72.7% for amitriptyline. Sertraline but not amitripty-line treatment determined a significant benefit on quality of life (PDQ-39 scale). We found no change in Unified Parkinson's Disease Rating Scale scores. However, the improvement in specific PDQ-39 subscores (mobility, activities of daily living, and stigma) suggests that depression affects patient self-perception of motor function and further emphasizes the need for its treament.

KW - Amitriptyline

KW - Depression

KW - Parkinson's disease

KW - Sertraline

UR - http://www.scopus.com/inward/record.url?scp=33748346259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748346259&partnerID=8YFLogxK

U2 - 10.1002/mds.20895

DO - 10.1002/mds.20895

M3 - Article

C2 - 16637039

AN - SCOPUS:33748346259

VL - 21

SP - 1119

EP - 1122

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 8

ER -